12 Health Care Stocks Moving In Monday's After-Market Session

Benzinga · 06/30 21:06
Gainers
- Milestone Scientific (AMEX:MLSS) shares moved upwards by 14.2% to $0.73 during Monday's after-market session. The market value of their outstanding shares is at $57.0 million.
- Telomir Pharmaceuticals (NASDAQ:TELO) stock increased by 10.39% to $1.38. The market value of their outstanding shares is at $45.5 million.
- Shattuck Labs (NASDAQ:STTK) shares rose 8.61% to $0.86. The market value of their outstanding shares is at $40.8 million.
- Cellectar Biosciences (NASDAQ:CLRB) shares moved upwards by 8.25% to $7.7. The market value of their outstanding shares is at $14.3 million.
- Rallybio (NASDAQ:RLYB) shares moved upwards by 7.8% to $0.35. The market value of their outstanding shares is at $13.8 million.
- Mersana Therapeutics (NASDAQ:MRSN) shares rose 6.72% to $0.32. The market value of their outstanding shares is at $36.2 million.
Losers
- Applied DNA Sciences (NASDAQ:APDN) shares decreased by 10.5% to $4.61 during Monday's after-market session. The market value of their outstanding shares is at $2.5 million.
- Xenetic Biosciences (NASDAQ:XBIO) shares fell 10.18% to $3.53. The company's market cap stands at $5.4 million.
- Dyne Therapeutics (NASDAQ:DYN) shares fell 8.62% to $8.7. The company's market cap stands at $1.0 billion.
- Axogen (NASDAQ:AXGN) stock declined by 7.75% to $10.01. The market value of their outstanding shares is at $478.2 million.
- Autonomix Medical (NASDAQ:AMIX) shares fell 7.01% to $1.46. The company's market cap stands at $5.5 million.
- Catheter Precision (AMEX:VTAK) shares declined by 6.78% to $0.23. The market value of their outstanding shares is at $2.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.